Syneos Health to Share Strategies Designed to Meet the Needs of Patients, Payers and Regulators at DIA Global Annual Meeting
June 22 2018 - 8:15AM
Syneos Health™ (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, today announced an
extensive presence at the DIA Global Annual Meeting being held June
24-28 in Boston, Mass. Numerous company thought leaders – including
data, real world and late phase, regulatory, feasibility,
technology, consulting and branding experts – will provide
strategic insights for developing therapies designed to achieve key
stakeholder objectives.
“Regulators are now joined by payers, and most
importantly engaged patients, in the growing list of stakeholders
biopharmaceutical companies must consider to deliver a successful
clinical program and product to the market,” said Alistair
Macdonald, Chief Executive Officer at Syneos Health. “At DIA, we’ll
discuss stakeholder-specific strategies and solutions fueled by
insights generated through our unique CRO and CCO (Contract
Commercial Organization) business model.”
Syneos Health thought leaders will share
perspectives during 11 educational sessions:
Monday, June 25
- Data Integrity Playbook – A Cross-Functional, Risk-Based,
Analytics-Driven Approach to Monitor Data Integrity: Gene Vinson,
Senior Director, Global Data Technologies, Biometrics (11:00 a.m. –
12:00 p.m.)
- The Evolving Biosimilars Landscape – A Medical Affairs
Perspective: Bryan Katz, Vice President, Integrated Solutions (3:00
p.m. – 4:15 p.m.)
Tuesday, June 26
- Oversight in the Era of E6 (R2): Melissa Bomben, Vice
President, Strategic Resourcing (8:00 a.m. – 9:00 a.m.)
- Global Regulatory Strategies for Biosimilars: Brittany Scott,
Creative Director, Addison Whitney, a Syneos Health company (8:00
a.m. – 9:15 a.m.)
- The European Medical Devices Regulation and MDUFA IV – One Year
On – Is it Any Clearer?: Angela Stokes, Senior Director, Global
Regulatory Consulting (10:30 a.m. – 11:45 a.m.)
- Redefining the Site Investigator's Experience: Earl Seltzer,
Director, Global Feasibility, Site and Patient Access (4:15 p.m. –
5:30 p.m.)
Wednesday, June 27
- Balancing Regulatory, Medical, and Operational Pillars to Get
Pediatric Trials Done Globally: Earl Seltzer (10:30 a.m. – 11:30
a.m.)
- DIA Clinical Pharmacology Community Round Table Discussion –
Evolution and Harmonization of First-in-Human Guidelines: Beatrice
Setnik, Vice President, Scientific and Clinical Strategy, Early
Phase (1:00 p.m. – 2:00 p.m.)
- First-In-Human Studies – An Examination of the Evolving
Regulatory and Clinical Practices to Ensure Subject Safety:
Beatrice Setnik (2:15 p.m. – 2:45 p.m.)
- Design and Statistical Considerations for Real World Evidence
to Support Regulatory Decision Making: David Thompson, Senior Vice
President, Real World and Late Phase Research (4:00 p.m. – 5:15
p.m.)
Thursday, June 28
- Improving Efficiency and Effectiveness in Data Management of
Pediatric, Rare Disease, and Oncology Trials: Vijayalakshmi
Angaiyan, Principal Clinical Data Manager (9:00 a.m. – 10:15
a.m.)
Recognizing Clinical Research
SitesSyneos Health will also host its fifth annual Site
Appreciation Reception for clinical site representatives at DIA on
Monday, June 25, from 7:00 p.m. to 10:00 p.m. The event, recognizes
significant site contributions to the drug development process.
Hosts Clare Grace, PhD, Vice President, Site and Patient Access,
and Tracey Gashi, PhD, Executive Director, Site and Patient Access,
will facilitate a discussion surrounding ways to improve future
collaboration on behalf of patients.
Connect with Syneos Health
- Schedule a meeting with Syneos Health experts at DIA
- Visit Booth #714
- Follow our DIA activities on LinkedIn and
Twitter
About Syneos HealthSyneos
Health™ (Nasdaq:SYNH) is the only fully integrated
biopharmaceutical solutions organization. Our company, including a
Contract Research Organization (CRO) and Contract Commercial
Organization (CCO), is purpose-built to accelerate customer
performance to address modern market realities. Created through the
merger of two industry leading companies – INC Research and
inVentiv Health – we bring together more than 21,000 clinical and
commercial minds with the ability to support customers in more than
110 countries. Together we share insights, use the latest
technologies and apply advanced business practices to speed our
customers’ delivery of important therapies to patients. To learn
more about how we are shortening the distance from lab to
life® visit syneoshealth.com.
Contact: Investor Relations
Contact:
Ronnie Speight
Vice President, Investor Relations
+1
919 745 2745
Investor.Relations@syneoshealth.com
Press/Media Contact:Danielle DeForgeExecutive
Director, External Communications+1 202 210
5992danielle.deforge@syneoshealth.com
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024